{"log_id": 3473958039399581075, "direction": 0, "words_result_num": 28, "words_result": [{"probability": {"variance": 0.001417, "average": 0.990601, "min": 0.759956}, "location": {"width": 834, "top": 254, "height": 29, "left": 250}, "words": "由于本品抑制CYP2C8和/或P糖蛋白(Pgp),本品与静脉给药的紫杉醇联用时使"}, {"probability": {"variance": 0.000644, "average": 0.994066, "min": 0.841132}, "location": {"width": 882, "top": 301, "height": 29, "left": 202}, "words": "紫杉醇的暴露量增加23%。临床试验中观察到这一联合用药时腹泻和中性粒细胞减少的"}, {"probability": {"variance": 5e-06, "average": 0.998502, "min": 0.990744}, "location": {"width": 609, "top": 348, "height": 29, "left": 202}, "words": "发生率和严重程度增加。建议本品与紫杉醇合用时应当谨慎"}, {"probability": {"variance": 0.000104, "average": 0.996828, "min": 0.940747}, "location": {"width": 836, "top": 394, "height": 29, "left": 250}, "words": "本品与静脉给药的多西紫杉醇合用时对2种活性药物的AUC或Cmax均无显著影"}, {"probability": {"variance": 2e-06, "average": 0.998939, "min": 0.994191}, "location": {"width": 558, "top": 441, "height": 28, "left": 205}, "words": "响。但多西紫杉醇引起的中性粒细胞减少的发生率升高"}, {"probability": {"variance": 0.000162, "average": 0.995394, "min": 0.92866}, "location": {"width": 836, "top": 485, "height": 29, "left": 249}, "words": "本品与伊立替康合用(作为 FOLFIRI方案的一部分)导致SN-38(伊立替康的活性"}, {"probability": {"variance": 0.003765, "average": 0.98688, "min": 0.609339}, "location": {"width": 882, "top": 531, "height": 30, "left": 203}, "words": "代谢产物)ALC增加约40%。这一相互作用的确切机制不明。本品与伊立替康合用应当"}, {"probability": {"variance": 0, "average": 0.999771, "min": 0.999595}, "location": {"width": 47, "top": 579, "height": 26, "left": 203}, "words": "谨慎"}, {"probability": {"variance": 3.3e-05, "average": 0.997513, "min": 0.969855}, "location": {"width": 836, "top": 623, "height": 29, "left": 248}, "words": "本品是转运蛋白Pgp和乳腺癌耐药蛋白(BCRP)的底物。这些蛋白的诱导剂和抑"}, {"probability": {"variance": 0.004221, "average": 0.984603, "min": 0.654391}, "location": {"width": 810, "top": 653, "height": 44, "left": 202}, "words": "制剂可能改变本品的暴露量和/或分布(参见【药代动力学】"}, {"probability": {"variance": 0.001359, "average": 0.988402, "min": 0.806376}, "location": {"width": 838, "top": 713, "height": 31, "left": 248}, "words": "本品在临床有效浓度时体外可抑制转运蛋白Pgp。本品与口服地高辛合用使地高辛"}, {"probability": {"variance": 4.5e-05, "average": 0.996398, "min": 0.970364}, "location": {"width": 786, "top": 759, "height": 31, "left": 203}, "words": "的AUC大约升高98%。本品与属于Pgp底物的治疗窗窄的药物合用时应当谨慎"}, {"probability": {"variance": 0.008032, "average": 0.975159, "min": 0.58232}, "location": {"width": 834, "top": 798, "height": 36, "left": 251}, "words": "本品在体外可抑制转运蛋白BCRP和OATP1B1。尚未评价这一作用的临床意义。不"}, {"probability": {"variance": 0.0009, "average": 0.991496, "min": 0.81702}, "location": {"width": 880, "top": 851, "height": 28, "left": 204}, "words": "能排除本品对BCRP的底物(例如拓扑替康)和OATP1B1的底物(例如罗苏伐他汀)的"}, {"probability": {"variance": 1e-06, "average": 0.999419, "min": 0.997208}, "location": {"width": 432, "top": 896, "height": 28, "left": 207}, "words": "药代动力学有影响(参见【药代动力学】)"}, {"probability": {"variance": 5e-06, "average": 0.998573, "min": 0.990318}, "location": {"width": 836, "top": 941, "height": 30, "left": 249}, "words": "本品与卡培他滨、来曲唑或曲妥珠单抗合用时,对这些药物(或卡培他滨的代谢"}, {"probability": {"variance": 1e-06, "average": 0.99885, "min": 0.99569}, "location": {"width": 398, "top": 988, "height": 28, "left": 202}, "words": "产物)或本品的药代动力学的影响不大"}, {"probability": {"variance": 0, "average": 0.989086, "min": 0.989086}, "location": {"width": 94, "top": 1055, "height": 23, "left": 853}, "words": " GUANGDONG"}, {"probability": {"variance": 2.6e-05, "average": 0.996747, "min": 0.987945}, "location": {"width": 177, "top": 1059, "height": 80, "left": 810}, "words": "华润广东"}, {"probability": {"variance": 0, "average": 0.97526, "min": 0.97526}, "location": {"width": 23, "top": 1067, "height": 21, "left": 952}, "words": "P"}, {"probability": {"variance": 0, "average": 0.999603, "min": 0.99865}, "location": {"width": 147, "top": 1079, "height": 31, "left": 211}, "words": "【药物过量】"}, {"probability": {"variance": 0.028812, "average": 0.90883, "min": 0.44425}, "location": {"width": 786, "top": 1120, "height": 39, "left": 247}, "words": "没有特异性的针对ErbB1(EGFR)和/或ErbB2酪氨酸激酸磷酸制剂的解"}, {"probability": {"variance": 0.010881, "average": 0.973913, "min": 0.452299}, "location": {"width": 671, "top": 1153, "height": 51, "left": 200}, "words": "剂。临床研究中本品曾用过的最大口服剂量是每天1800m0"}, {"probability": {"variance": 1.2e-05, "average": 0.998834, "min": 0.979029}, "location": {"width": 815, "top": 1241, "height": 28, "left": 248}, "words": "增加本品给药次数可导致血清浓度超过临床试验中观察到的数值,因此漏服的剂"}, {"probability": {"variance": 1.2e-05, "average": 0.998517, "min": 0.980988}, "location": {"width": 762, "top": 1285, "height": 28, "left": 201}, "words": "量不能补服,在下一次服药时间按计划继续服药即可(参见【用法用量】)"}, {"probability": {"variance": 1e-06, "average": 0.998988, "min": 0.997552}, "location": {"width": 119, "top": 1355, "height": 27, "left": 201}, "words": "症状和体征"}, {"probability": {"variance": 6e-06, "average": 0.999056, "min": 0.986606}, "location": {"width": 849, "top": 1424, "height": 28, "left": 235}, "words": "接受本品治疗的患者中报告过无症状和有症状的药物过量病例。已报告的每天服用"}, {"probability": {"variance": 0.000105, "average": 0.995284, "min": 0.946887}, "location": {"width": 885, "top": 1468, "height": 30, "left": 200}, "words": "剂量范围从2500mg到9000mg,持续时间从1天到17天。观察到的症状包括已知与本品"}], "language": 3}